DCM
VNDA icon

Delpha Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Delpha Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,153
Closed -$33K – 1185
2017
Q4 		$33K Buy
+2,153
New +$32K 0.04% 514

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Delpha Capital Management's VNDA Position: Q1 2018 in Review

Delpha Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q1 2018, closing a stake of 2,153 shares — an estimated $33K sold.

Delpha Capital Management first reported a position in VNDA in Q4 2017 and held it in 1 quarter. The position peaked at $33K in Q4 2017. 131 funds tracked by Wall St. Rank hold VNDA as of Q1 2018.

  • Delpha Capital Management reported no remaining Vanda Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 2,153 Vanda Pharmaceuticals shares in Q1 2018, an estimated $33K.
  • Delpha Capital Management first reported a position in Vanda Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Vanda Pharmaceuticals position peaked at $33K in Q4 2017.
  • 131 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.